Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hierl

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|February 24, 2024
Emerging Gene Therapeutics for Epidermolysis Bullosa under DevelopmentJohannes Bischof, Markus Hierl, Ulrich Koller
ACS Omega|January 23, 2023
Tritium Labeling of Neuromedin S by Conjugation with [<sup>3</sup>H]<i>N</i>-Succinimidyl PropionateMartin R Edelmann, Johannes Erny, Wolfgang Guba, et al.
Free Radical Biology & Medicine|May 22, 2003
Cloning of novel human SEC14p-like proteins: ligand binding and functional propertiesPetra Kempná, Jean-Marc Zingg, Roberta Ricciarelli, et al.
Journal of Medicinal Chemistry|July 14, 2025
Machine Learning-Assisted Iterative Screening for Efficient Detection of Drug Discovery Starting PointsAlex T Müller, Markus Hierl, Dominik Heer, et al.
Journal of Biomolecular Screening|August 24, 2011
High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylasesVioleta Yu, Tanja Fisch, Alexander M Long, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2008
Synthesis and activity of substituted carbamates as potentiators of the alpha4beta2 nicotinic acetylcholine receptorStephanie K Springer, Katrina S Woodin, Virginia Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2008
Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiatorsBrian K Albrecht, Virginia Berry, Alessandro A Boezio, et al.
Cell Chemical Biology|December 2, 2023
Selective and brain-penetrant HCN1 inhibitors reveal links between synaptic integration, cortical function, and working memoryEva Harde, Markus Hierl, Michael Weber, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2025
Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosaMarkus Hierl, Johannes Bischof, Bernadette Liemberger, et al.
Pain|February 20, 2010
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent painBaoXi Gao, Markus Hierl, Kristie Clarkin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|February 24, 2024
Emerging Gene Therapeutics for Epidermolysis Bullosa under DevelopmentJohannes Bischof, Markus Hierl, Ulrich Koller
ACS Omega|January 23, 2023
Tritium Labeling of Neuromedin S by Conjugation with [<sup>3</sup>H]<i>N</i>-Succinimidyl PropionateMartin R Edelmann, Johannes Erny, Wolfgang Guba, et al.
Free Radical Biology & Medicine|May 22, 2003
Cloning of novel human SEC14p-like proteins: ligand binding and functional propertiesPetra Kempná, Jean-Marc Zingg, Roberta Ricciarelli, et al.
Journal of Medicinal Chemistry|July 14, 2025
Machine Learning-Assisted Iterative Screening for Efficient Detection of Drug Discovery Starting PointsAlex T Müller, Markus Hierl, Dominik Heer, et al.
Journal of Biomolecular Screening|August 24, 2011
High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylasesVioleta Yu, Tanja Fisch, Alexander M Long, et al.
Bioorganic & Medicinal Chemistry Letters|September 23, 2008
Synthesis and activity of substituted carbamates as potentiators of the alpha4beta2 nicotinic acetylcholine receptorStephanie K Springer, Katrina S Woodin, Virginia Berry, et al.
Bioorganic & Medicinal Chemistry Letters|September 16, 2008
Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiatorsBrian K Albrecht, Virginia Berry, Alessandro A Boezio, et al.
Cell Chemical Biology|December 2, 2023
Selective and brain-penetrant HCN1 inhibitors reveal links between synaptic integration, cortical function, and working memoryEva Harde, Markus Hierl, Michael Weber, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 1, 2025
Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosaMarkus Hierl, Johannes Bischof, Bernadette Liemberger, et al.
Pain|February 20, 2010
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent painBaoXi Gao, Markus Hierl, Kristie Clarkin, et al.
Pageof 2